﻿{"id":1386,"date":"2016-06-19T17:42:29","date_gmt":"2016-06-19T15:42:29","guid":{"rendered":"http:\/\/www.ematologialasapienza.it\/?page_id=1386"},"modified":"2023-11-14T18:12:01","modified_gmt":"2023-11-14T17:12:01","slug":"news-ed-eventi","status":"publish","type":"page","link":"https:\/\/www.ematologialasapienza.it\/?page_id=1386","title":{"rendered":"Contributi ed eventi"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container hundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-overflow:visible;--awb-padding-right:30px;--awb-padding-left:30px;--awb-margin-top:10px;--awb-margin-bottom:10px;--awb-background-color:rgba(255,255,255,0);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"width:104% !important;max-width:104% !important;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column fusion-flex-align-self-flex-start fusion-column-no-min-height\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;width:100%;\"><\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container hundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-overflow:visible;--awb-padding-right:30px;--awb-padding-left:30px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"width:104% !important;max-width:104% !important;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_1 1_1 fusion-flex-column fusion-flex-align-self-flex-start fusion-column-no-min-height\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-image-element \" style=\"text-align:center;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing);\"><span class=\" fusion-imageframe imageframe-none imageframe-1 hover-type-none\"><img decoding=\"async\" width=\"1950\" height=\"420\" title=\"compositNewsEventi1950x420\" src=\"https:\/\/www.ematologialasapienza.it\/wp-content\/uploads\/2016\/06\/compositNewsEventi1950x420.jpg\" alt class=\"img-responsive wp-image-1513\" srcset=\"https:\/\/www.ematologialasapienza.it\/wp-content\/uploads\/2016\/06\/compositNewsEventi1950x420-300x65.jpg 300w, https:\/\/www.ematologialasapienza.it\/wp-content\/uploads\/2016\/06\/compositNewsEventi1950x420-768x165.jpg 768w, https:\/\/www.ematologialasapienza.it\/wp-content\/uploads\/2016\/06\/compositNewsEventi1950x420-1024x221.jpg 1024w, https:\/\/www.ematologialasapienza.it\/wp-content\/uploads\/2016\/06\/compositNewsEventi1950x420.jpg 1950w\" sizes=\"(max-width: 1950px) 100vw, 1950px\" \/><\/span><\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-3 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-background-position:left top;--awb-border-sizes-top:0px;--awb-border-sizes-bottom:0px;--awb-border-sizes-left:0px;--awb-border-sizes-right:0px;--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-top:50px;--awb-padding-right:20px;--awb-padding-bottom:20px;--awb-padding-left:20px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_1 1_1 fusion-flex-column fusion-flex-align-self-flex-start fusion-column-no-min-height\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-top:30px;width:100%;\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-top:-10px;width:100%;\"><\/div><div class=\"fusion-title title fusion-title-1 fusion-title-text fusion-title-size-two\" style=\"--awb-sep-color:#1e73be;\"><div class=\"title-sep-container title-sep-container-left fusion-no-large-visibility fusion-no-medium-visibility fusion-no-small-visibility\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#1e73be;\"><\/div><\/div><span class=\"awb-title-spacer fusion-no-large-visibility fusion-no-medium-visibility fusion-no-small-visibility\"><\/span><h2 class=\"fusion-title-heading title-heading-left fusion-responsive-typography-calculated\" style=\"margin:0;--fontSize:16;--minFontSize:16;line-height:1.5;\">Contributi<\/h2><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container title-sep-container-right\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#1e73be;\"><\/div><\/div><\/div><div class=\"fusion-blog-shortcode fusion-blog-shortcode-1 fusion-blog-archive fusion-blog-layout-medium-alternate fusion-blog-pagination\" style=\"--awb-title-font-size:18px;--awb-timeline-title-font-size:20px;--awb-title-font-family:-apple-system, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, Oxygen-Sans, Ubuntu, Cantarell, &#039;Helvetica Neue&#039; ,sans-serif;--awb-title-font-style:normal;--awb-title-font-weight:400;--awb-timeline-title-font-family:-apple-system, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, Oxygen-Sans, Ubuntu, Cantarell, &#039;Helvetica Neue&#039; ,sans-serif;--awb-timeline-title-font-style:normal;--awb-timeline-title-font-weight:400;\"><div class=\"fusion-posts-container fusion-posts-container-pagination fusion-blog-rollover\" data-pages=\"9\"><article id=\"blog-1-post-11812\" class=\"fusion-post-medium-alternate post-11812 post type-post status-publish format-standard hentry category-senza-categoria\">\n<div class=\"fusion-date-and-formats\"><div class=\"fusion-date-box updated\"><span class=\"fusion-date\">15<\/span><span class=\"fusion-month-year\">07, 2022<\/span><\/div><div class=\"fusion-format-box\"><i class=\"awb-icon-pen\" aria-hidden=\"true\"><\/i><\/div><\/div>\t<style type=\"text\/css\">\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\t<\/style>\n\n\n<div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=11812\">\u201cPhiladelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia\u201d. La review pubblicata sul New England Journal of Medicine<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/www.ematologialasapienza.it\/?author=1\" title=\"Articoli scritti da rb.ricci\" rel=\"author\">rb.ricci<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2023-11-14T15:27:01+01:00<\/span><span>Luglio 15th, 2022<\/span><span class=\"fusion-inline-sep\">|<\/span>Categories: <a href=\"https:\/\/www.ematologialasapienza.it\/?cat=1\" rel=\"category\">Senza categoria<\/a><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-post-content-container\"><p>E\u2019 stata pubblicata il 23 giugno sul New England Journal of Medicine la review \u201cPhiladelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia\u201d a firma di Robin Fo\u00e0 e Sabina Chiaretti. E\u2019 il coronamento di una storia iniziata quasi 20 anni orsono, quando fu condotto il primo studio GIMEMA per il trattamento di quella che allora era la peggior neoplasia ematologica, utilizzando in induzione solo l\u2019inibitore delle tirosin-chinasi (TKI) imatinib in pazienti con leucemia acuta linfoblastica (LAL) Ph+ di et\u00e0 superiore a 60 anni. [...]<\/p><\/div><\/div><div class=\"fusion-clearfix\"><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignright\"><a class=\"fusion-read-more\" href=\"https:\/\/www.ematologialasapienza.it\/?p=11812\" aria-label=\"More on \u201cPhiladelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia\u201d. La review pubblicata sul New England Journal of Medicine\">Read More<\/a><\/div><\/div><\/article>\n<article id=\"blog-1-post-11687\" class=\"fusion-post-medium-alternate post-11687 post type-post status-publish format-standard hentry category-pubblicazione\">\n<div class=\"fusion-date-and-formats\"><div class=\"fusion-date-box updated\"><span class=\"fusion-date\">2<\/span><span class=\"fusion-month-year\">03, 2021<\/span><\/div><div class=\"fusion-format-box\"><i class=\"awb-icon-pen\" aria-hidden=\"true\"><\/i><\/div><\/div>\t<style type=\"text\/css\">\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\t<\/style>\n\n\n<div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=11687\">Commento all\u2019articolo \u201cDasatinib-Blinatumomab for Ph-positive Acute Lymphoblastic Leukemia in Adults\u201d (NEJM)<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/www.ematologialasapienza.it\/?author=1\" title=\"Articoli scritti da rb.ricci\" rel=\"author\">rb.ricci<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2023-11-14T15:27:01+01:00<\/span><span>Marzo 2nd, 2021<\/span><span class=\"fusion-inline-sep\">|<\/span>Categories: <a href=\"https:\/\/www.ematologialasapienza.it\/?cat=40\" rel=\"category\">Pubblicazione<\/a><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-post-content-container\"><p>   A fine Ottobre 2020 sono stati pubblicati sul New England Journal of Medicine1 i risultati del prototocollo clinico GIMEMA LAL2116 \u2018D-ALBA Front-Line Sequential Treatment of Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) patients with Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab\u2019. Lo studio che ha coinvolto 63 pazienti adulti con leucemia acuta linfoblastica Philadelphia positiva (LAL Ph+) di nuova diagnosi ha dimostrato l\u2019elevata efficacia e la ridotta tossicit\u00e0 di un trattamento di induzione e consolidamento [...]<\/p><\/div><\/div><div class=\"fusion-clearfix\"><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignright\"><a class=\"fusion-read-more\" href=\"https:\/\/www.ematologialasapienza.it\/?p=11687\" aria-label=\"More on Commento all\u2019articolo \u201cDasatinib-Blinatumomab for Ph-positive Acute Lymphoblastic Leukemia in Adults\u201d (NEJM)\">Read More<\/a><\/div><\/div><\/article>\n<article id=\"blog-1-post-11654\" class=\"fusion-post-medium-alternate post-11654 post type-post status-publish format-standard hentry category-senza-categoria\">\n<div class=\"fusion-date-and-formats\"><div class=\"fusion-date-box updated\"><span class=\"fusion-date\">6<\/span><span class=\"fusion-month-year\">04, 2020<\/span><\/div><div class=\"fusion-format-box\"><i class=\"awb-icon-pen\" aria-hidden=\"true\"><\/i><\/div><\/div>\t<style type=\"text\/css\">\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\t<\/style>\n\n\n<div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=11654\">Emergenza Covid-19 \u2013 Link a Ematologia in Progress<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/www.ematologialasapienza.it\/?author=3\" title=\"Articoli scritti da editor contenuti\" rel=\"author\">editor contenuti<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2023-11-14T15:27:01+01:00<\/span><span>Aprile 6th, 2020<\/span><span class=\"fusion-inline-sep\">|<\/span>Categories: <a href=\"https:\/\/www.ematologialasapienza.it\/?cat=1\" rel=\"category\">Senza categoria<\/a><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-post-content-container\"><p>La crisi legata alla pandemia di Covid-19 sta creando momenti difficilissimi in tutti i comparti dell\u2019assistenza sanitaria, incluso il campo dell\u2019Ematologia. Sul sito Ematologia in Progress, un progetto educazionale contenente sezioni ed approfondimenti sulle diverse patologie ematologiche a cura di esperti qualificati, \u00e8 stata inaugurata una sezione dedicata alla Emergenza Covid-19, con link a risorse educazionali ed articoli scientifici sull\u2019argomento. Cliccando sul link: Emergenza Covid-19 \u00e8 possibile accedere alla pagina di Ematologia in Progress dedicata a Covid-19.<\/p><\/div><\/div><div class=\"fusion-clearfix\"><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignright\"><a class=\"fusion-read-more\" href=\"https:\/\/www.ematologialasapienza.it\/?p=11654\" aria-label=\"More on Emergenza Covid-19 \u2013 Link a Ematologia in Progress\">Read More<\/a><\/div><\/div><\/article>\n<article id=\"blog-1-post-11602\" class=\"fusion-post-medium-alternate post-11602 post type-post status-publish format-standard hentry category-congresso category-didattica category-ricerca\">\n<div class=\"fusion-date-and-formats\"><div class=\"fusion-date-box updated\"><span class=\"fusion-date\">11<\/span><span class=\"fusion-month-year\">02, 2020<\/span><\/div><div class=\"fusion-format-box\"><i class=\"awb-icon-pen\" aria-hidden=\"true\"><\/i><\/div><\/div>\t<style type=\"text\/css\">\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\t<\/style>\n\n\n<div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=11602\">Report Extra Day CAR-T cells &#8211; Roma 28 Ottobre 2019<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/www.ematologialasapienza.it\/?author=1\" title=\"Articoli scritti da rb.ricci\" rel=\"author\">rb.ricci<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2023-11-14T15:27:01+01:00<\/span><span>Febbraio 11th, 2020<\/span><span class=\"fusion-inline-sep\">|<\/span>Categories: <a href=\"https:\/\/www.ematologialasapienza.it\/?cat=39\" rel=\"category\">Congresso<\/a>, <a href=\"https:\/\/www.ematologialasapienza.it\/?cat=41\" rel=\"category\">Didattica<\/a>, <a href=\"https:\/\/www.ematologialasapienza.it\/?cat=42\" rel=\"category\">Ricerca clinica<\/a><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-post-content-container\"><p>Il terzo\u00a0Extra Day\u00a0del progetto\u00a0Hematology Passport\u00a0per il 2019, dedicato alle\u00a0CAR-T Cells, si \u00e8 svolto a Roma, presso l\u2019Hotel Giustiniano, nella giornata di luned\u00ec\u00a028 ottobre 2019. Gli Extra Days sono parte integrante del progetto Hematology Passport e mirano a fornire ai giovani ematologi delle occasioni di incontro, apprendimento e confronto con i migliori esperti. Il tema di questo Extra Day, le cellule CAR-T ed il loro utilizzo clinico, esemplifica l\u2019evoluzione rapida e costante dell\u2019Ematologia degli ultimi anni e rappresenta un argomento di [...]<\/p><\/div><\/div><div class=\"fusion-clearfix\"><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignright\"><a class=\"fusion-read-more\" href=\"https:\/\/www.ematologialasapienza.it\/?p=11602\" aria-label=\"More on Report Extra Day CAR-T cells &#8211; Roma 28 Ottobre 2019\">Read More<\/a><\/div><\/div><\/article>\n<article id=\"blog-1-post-11492\" class=\"fusion-post-medium-alternate post-11492 post type-post status-publish format-standard hentry category-senza-categoria\">\n<div class=\"fusion-date-and-formats\"><div class=\"fusion-date-box updated\"><span class=\"fusion-date\">10<\/span><span class=\"fusion-month-year\">01, 2020<\/span><\/div><div class=\"fusion-format-box\"><i class=\"awb-icon-pen\" aria-hidden=\"true\"><\/i><\/div><\/div>\t<style type=\"text\/css\">\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\t<\/style>\n\n\n<div class=\"fusion-post-content post-content\"><h2 class=\"blog-shortcode-post-title entry-title\"><a href=\"https:\/\/www.ematologialasapienza.it\/?p=11492\">Efficacia clinica del nuovo inibitore allosterico di BCR-ABL asciminib nei pazienti con LMC<\/a><\/h2><p class=\"fusion-single-line-meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/www.ematologialasapienza.it\/?author=3\" title=\"Articoli scritti da editor contenuti\" rel=\"author\">editor contenuti<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2023-11-14T15:27:01+01:00<\/span><span>Gennaio 10th, 2020<\/span><span class=\"fusion-inline-sep\">|<\/span>Categories: <a href=\"https:\/\/www.ematologialasapienza.it\/?cat=1\" rel=\"category\">Senza categoria<\/a><span class=\"fusion-inline-sep\">|<\/span><\/p><div class=\"fusion-post-content-container\"><p>Sono stati pubblicati sul New England Journal of Medicine i risultati dello studio (1) di fase 1 che ha fornito i primi dati di efficacia e tollerabilit\u00e0 del nuovo inibitore di BCR-ABL asciminib nei pazienti con leucemia mieloide cronica (LMC): in una popolazione pesantemente pre-trattata, resistente o intollerante agli inibitori tirosin-chinasici (TKI), asciminib ha mostrato un\u2019azione specifica e selettiva, in assenza di effetti collaterali importanti, aprendo la strada a nuove possibilit\u00e0 terapeutiche in questi pazienti. Asciminib \u00e8 il primo esempio [...]<\/p><\/div><\/div><div class=\"fusion-clearfix\"><\/div><div class=\"fusion-meta-info\"><div class=\"fusion-alignright\"><a class=\"fusion-read-more\" href=\"https:\/\/www.ematologialasapienza.it\/?p=11492\" aria-label=\"More on Efficacia clinica del nuovo inibitore allosterico di BCR-ABL asciminib nei pazienti con LMC\">Read More<\/a><\/div><\/div><\/article>\n<\/div><div class=\"pagination clearfix\"><span class=\"current\">1<\/span><a href=\"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=%2Fwp%2Fv2%2Fpages%2F1386&#038;paged=2\" class=\"inactive\">2<\/a><a class=\"pagination-next\" rel=\"next\" href=\"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=%2Fwp%2Fv2%2Fpages%2F1386&#038;paged=2\"><span class=\"page-text\">Prossimo<\/span><span class=\"page-next\"><\/span><\/a><\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/pages\/1386"}],"collection":[{"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1386"}],"version-history":[{"count":75,"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/pages\/1386\/revisions"}],"predecessor-version":[{"id":12141,"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=\/wp\/v2\/pages\/1386\/revisions\/12141"}],"wp:attachment":[{"href":"https:\/\/www.ematologialasapienza.it\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}